Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT0591CP in Relapsed or Refractory Multiple Myeloma
NCT05486975Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Aug 2022
- Primary completion
- Jan 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT0591CP in multiple myeloma (MM), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Safety and tolerability at 4 weeks. Status: unknown.
02
Drugs
CT0591CP
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05486975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05486975.